EAM Investors’s Regenxbio RGNX Stock Holding History

EAM Investors’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-29,195	Closed	-$2.2M	–	311
2018 Q3	$2.2M	Sell	29,195 -8,225	-22%	-$593K	0.33%	145
2018 Q2	$2.69M	Buy	+37,420	New	+$1.79M	0.42%	118
2017 Q3	–	Sell	-113,821	Closed	-$2.25M	–	336
2017 Q2	$2.25M	Sell	113,821 -36,265	-24%	-$702K	0.37%	138
2017 Q1	$2.9M	Sell	150,086 -11,122	-7%	-$215K	0.46%	95
2016 Q4	$2.99M	Buy	+161,208	New	+$3.08M	0.4%	107

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

EAM Investors's RGNX Position: Q4 2018 in Review

EAM Investors sold out of Regenxbio (RGNX) in Q4 2018, closing a stake of 29,195 shares — an estimated $2.2M sold.

EAM Investors first reported a position in RGNX in Q4 2016 and held it in 5 quarters. The position peaked at $2.99M in Q4 2016. 183 funds tracked by Wall St. Rank hold RGNX as of Q4 2018.

EAM Investors reported no remaining Regenxbio position as of Q4 2018 after selling out during the quarter.
EAM Investors sold 29,195 Regenxbio shares in Q4 2018, an estimated $2.2M.
EAM Investors first reported a position in Regenxbio in Q4 2016 and held it in 5 quarters.
EAM Investors's Regenxbio position peaked at $2.99M in Q4 2016.
183 funds tracked by Wall St. Rank held Regenxbio as of Q4 2018.

Based on EAM Investors's 13F filing for Q4 2018, filed 13 Feb 2019.